Clinical trial
Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the…
NCT00317499 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00317499 |
|---|---|
| Title | Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis |
| Official title | Double-Blind, Randomized, Placebo-Controlled Study of Etanercept (ENBREL) in the Treatment of Psoriatic Arthritis (PsA) and Psoriasis |
| Lead sponsor | Amgen, Industry |
| Collaborators | Immunex Corporation Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis, Psoriasis |
| Intervention type | Drug, Other |
| Interventions | Placebo, Etanercept |
| Enrollment | 205 |
| Start date | Apr 1, 2000 |
| Primary completion | Jun 1, 2002 |
| Completion | Jul 1, 2002 |
| First posted | Apr 25, 2006 |
| Last update posted | Dec 23, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: